Impact of baseline clinical parameters on NSCLC patients.

<p>Impact of baseline clinical parameters on NSCLC patients.</p

Inclusion and patient selection.

<p>Inclusion and patient selection.</p

The impact of <i>de novo</i> liver metastasis on clinical outcome in patients with advanced non-small-cell lung cancer

<div><p>Liver metastasis has been found to affect outcome in prostate cancer and colorectal cancer, but its role in lung cancer is unclear. The current study aimed to evaluate the impact of <i>de novo</i> liver metastasis (DLM) on stage IV non-small cell lung cancer (NSCLC) outcomes and to examine whether tyrosine kinase inhibitors (TKI) reverse poor prognosis in patients with DLM and epidermal growth factor receptor (EGFR)-mutant NSCLC. Among 1392 newly diagnosed NSCLC patients, 490 patients with stage IV disease treated between November 2010 and March 2014 at Kaohsiung Chang Gung Memorial Hospital were included. Patients were divided into two groups according to DLM status. There were 75 patients in the DLM group and 415 patients in the non-DLM group. The DLM group included more patients with bone metastasis, fewer patients with a lymphocyte-to-monocyte ratio (LMR) > 3.1, and fewer patients with pleural metastasis. In the DLM group, Eastern Cooperative Oncology Group performance status 3–4 and LMR ≦3.1 were associated with poor outcome. In patients without DLM, overall survival (OS) was longer in patients with EGFR-mutant NSCLC than in those without (20.2 vs. 7.3 months, p < 0.001). Among DLM patients, OS was similar between the EGFR-mutant and wild-type EGFR tumor subgroups (11.9 vs. 7.7 months, p = 0.155). We found that DLM was a significant poor prognostic factor in the EGFR-mutant patients treated with EGFR-TKIs, whereas DLM did not affect the prognosis of EGFR-wild-type patients.</p></div

Impact of baseline clinical parameters on NSCLC patients with <i>de novo</i> liver metastasis.

<p>Impact of baseline clinical parameters on NSCLC patients with <i>de novo</i> liver metastasis.</p

Overall survival of patients with liver plus other distant metastasis.

<p>Overall survival of patients with liver plus other distant metastasis.</p

Comparison of baseline clinical parameters between NSCLC patients with or without liver metastasis.

<p>Comparison of baseline clinical parameters between NSCLC patients with or without liver metastasis.</p

Overall survival regarding <i>de novo</i> liver metastasis and epidermal growth factor receptor mutation status.

<p>Overall survival regarding <i>de novo</i> liver metastasis and epidermal growth factor receptor mutation status.</p

Progression-free survival regarding <i>de novo</i> liver metastasis and epidermal growth factor receptor mutation status.

<p>Progression-free survival regarding <i>de novo</i> liver metastasis and epidermal growth factor receptor mutation status.</p

Immune profiles and clinical outcomes between sepsis patients with or without active cancer requiring admission to intensive care units

<div><p>Background</p><p>Immunoparalysis was observed in both patients with cancer and sepsis. In cancer patients, Cytotoxic T lymphocyte antigen-4 and programmed cell death protein 1/programmed death-ligand 1 axis are two key components of immunoparalysis. Several emerging therapies against these two axes gained significant clinical benefit. In severe sepsis patients, immunoparalysis was known as compensatory anti-inflammatory response syndrome and this has been suggested as an important cause of death in patients with sepsis. It would be interesting to see if immune status was different in severe sepsis patients with or without active cancer. The aim of this study was to assess the differences in immune profiles, and clinical outcomes between severe sepsis patients with or without cancer admitted to ICU.</p><p>Methods</p><p>A combined retrospective and prospective observational study from a cohort of adult sepsis patients admitted to three medical ICUs at Kaohsiung Chang Gung Memorial Hospital in Taiwan between August 2013 and June 2016.</p><p>Results</p><p>Of the 2744 patients admitted to the ICU, 532 patients with sepsis were included. Patients were divided into those with or without active cancer according to their medical history. Of the 532 patients, 95 (17.9%) patients had active cancer, and 437 (82.1%) patients had no active cancer history. Patients with active cancer were younger (p = 0.001) and were less likely to have diabetes mellitus (p < 0.001), hypertension (p < 0.001), coronary artery disease (p = 0.004), chronic obstructive pulmonary disease (p = 0.002) or stroke (p = 0.002) compared to patients without active cancer. Patients with active cancer also exhibited higher baseline lactate levels (p = 0.038), and higher baseline plasma interleukin (IL)-10 levels (p = 0.040), higher trend of granulocyte colony-stimulating factor (G-CSF) (p = 0.004) compared to patients without active cancer. The 14-day, 28-day and 90-day mortality rates were higher for patients with active cancer than those without active cancer (P < 0.001 for all intervals).</p><p>Conclusions</p><p>Among patients admitted to the ICU with sepsis, those with underling active cancer had higher baseline levels of plasma IL-10, higher trend of G-CSF and higher mortality rate than those without active cancer.</p></div

Additional file 1 of Risk factors for prolonged mechanical ventilation in critically ill patients with influenza-related acute respiratory distress syndrome

Additional file 1: Table S1. Characteristics of the 263 subjects with influenza-related ARDS. Table S2. Risk factors for PMV or death before MV D21 in subjects with influenza-related ARDS. Table S3.Characteristics of the subjects with influenza-related ARDS and MV use > 7 days. Table S4. Risk factors for PMV in patients with influenza-related ARDS